
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc. demonstrates a positive outlook driven by its innovative therapies targeting disease-causing proteins through its proprietary PROTAC technology. The company’s product candidates, particularly ARV-806, showcase significant pharmacologic advantages over current treatments, exhibiting over 40 times greater potency in reducing KRAS G12D proteins and more than 25 times improved inhibition of 3D spheroid proliferation compared to traditional KRAS inhibitors. Additionally, the potential for enhanced safety and efficacy, particularly in combination regimens, positions Arvinas favorably in the biopharmaceutical landscape, especially with the upcoming approval milestone for vepdeg in June 2025.
Bears say
The financial outlook for Arvinas Inc appears negative due to a combination of decreased projected revenues and challenges in maintaining competitive advantage. Specifically, a significant reduction in peak revenue expectations for vepdeg from $641.2 million to $296.9 million indicates a concerning shift in market penetration and investment viability, highlighting potential risks in the commercialization of their therapies. Furthermore, limited access to capital and funding may hinder the company's operational capabilities, ultimately postponing their path to profitability and cash flow generation.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares